A behavioral therapy called pivotal response treatment may boost the communication skills of autistic children with language delay better than do standard speech and autism therapies.

A drug that treats tumors and epilepsy in people with tuberous sclerosis complex does not boost their intelligence or ease autism traits.

People tend to believe that, regardless of the treatment, more is always better. But is it?

Watch the complete replay of Mark Bear discussing the latest research on treatments for fragile X syndrome.

Clinical trials of autism treatments rarely use a consistent set of tools to measure efficacy, making it tough to compare the treatments.

Following pushback from scientists, the U.S. National Institutes of Health has issued a two-year delay on a rule requiring basic researchers to register their studies as clinical trials.

Envisioned as bioRxiv’s clinical cousin, the new preprint server medRxiv hosts unpublished manuscripts describing original medical research.

Results from a new trial suggest that it’s safe to treat autistic children with umbilical cord stem cells. But parents must pay for the pricey infusions, and no one knows how or if the cells work.

A drug that mimics the hormone vasopressin improves social skills in autistic people — but so does one that blocks vasopressin’s effects. How can seemingly opposing manipulations produce similar results?

The lack of people with intellectual disability in studies of autism has a profound effect on our understanding of the condition.